Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Shattuck Labs announced a Phase 2 trial (RECEPTIVE-HS1) of its lead DR3-blocking antibody SL-325 in moderate to severe hidradenitis suppurativa, its second Phase 2 indication beyond IBD. The randomized, placebo-controlled trial will enroll roughly 150 patients with a 16-week treatment period; IND submission is expected in October 2026 and Week 16 HiSCR50 data in the first half of 2028. The company also appointed Dr. Shoba Ravichandran, formerly of Novartis where she led Cosentyx's global approval in HS, as SVP Clinical Development to lead the program.
Key figures
- Drug Name
- SL-325
- Phase Of Trial
- Phase 2
- Enrollment
- 150
- Trial name
- RECEPTIVE-HS1
- Cash runway
- into 2029
- Data timing
- first half of 2028
- Ind submission
- October 2026
- Primary endpoint
- HiSCR50 at Week 16
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.